Tunicamycin Enhances Cancer Drug Toxicity in Resistant Ovarian Cells
Author Information
Author(s): Hiss Donavon C, Gabriels Gary A, Folb Peter I
Primary Institution: University of Cape Town
Hypothesis
Can tunicamycin enhance the effectiveness of anticancer drugs in multidrug-resistant ovarian cancer cells?
Conclusion
Tunicamycin significantly increases the toxicity of various anticancer drugs in multidrug-resistant ovarian cancer cells.
Supporting Evidence
- Tunicamycin decreased the EC50 for doxorubicin, epirubicin, vincristine, and cisplatin, enhancing their cytotoxicity.
- Tunicamycin prolonged the intracellular retention time of vincristine.
- Tunicamycin increased the binding of doxorubicin and azidopine to the cells.
Takeaway
Tunicamycin helps cancer drugs work better in stubborn ovarian cancer cells that usually resist treatment.
Methodology
The study examined the effects of tunicamycin on drug sensitivity, uptake, efflux, and binding in ovarian cancer cells using various anticancer drugs.
Participant Demographics
The study used the UWOV2 ovarian cancer cell line derived from a patient resistant to chemotherapy.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI: 10.34 to 53.96
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website